{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:37:54Z","timestamp":1762144674141},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,8,15]],"date-time":"2009-08-15T00:00:00Z","timestamp":1250294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2009,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Botulinum Toxin Type-A (BoNT\/A) intraprostatic injection can induce prostatic involution and improve LUTS and urinary flow in patients with Benign Prostatic Enlargement (BPE). However, the duration of these effects is unknown. The objective of this work was to determine the duration of prostate volume reduction after one single intraprostatic injection of 200U of Botulinum Toxin Type-A.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is an extension of a 6 month study in which 21 frail elderly patients with refractory urinary retention and unfit for surgery were submitted to intraprostatic injection of BoNT\/A-200U, by ultrasound guided transrectal approach. In spite of frail conditions, eleven patients could be followed during 18 months. Prostate volume, total serum PSA, maximal flow rate (Qmax), residual volume (PVR) and IPSS-QoL scores were determined at 1, 3, 6, 12 and 18 months post-treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Mean prostate volume at baseline, 82 \u00b1 16 ml progressively decreased from month one coming to 49 \u00b1 9,5 ml (p = 0,003) at month six. From this moment on, prostate volume slowly recovered, becoming identical to baseline at 18 months (73 \u00b1 16 ml, p = 0.03). Albeit non significant, serum PSA showed a 25% decrease from baseline to month 6. The 11 patients resumed spontaneous voiding at month one. Mean Qmax was 11,3 \u00b1 1,7 ml\/sec and remained unchanged during the follow-up period. PVR ranged from 55 \u00b1 17 to 82 \u00b1 20 ml and IPSS score from10 to 12 points.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Intraprostatic BoNT\/A injection is safe and can reduce prostate volume for a period of 18 months. During this time a marked symptomatic improvement can be maintained.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2490-9-9","type":"journal-article","created":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T06:13:42Z","timestamp":1250576022000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment"],"prefix":"10.1186","volume":"9","author":[{"given":"Jo\u00e3o","family":"Silva","sequence":"first","affiliation":[]},{"given":"Rui","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Tiago","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Botelho","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Dinis","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2009,8,15]]},"reference":[{"issue":"Suppl 6","key":"135_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/nau.20479","volume":"26","author":"F Cruz","year":"2007","unstructured":"Cruz F, Dinis P: Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourol Urodyn. 2007, 26 (Suppl 6): 920-7. 10.1002\/nau.20479.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"135_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0090-4295(03)00477-1","volume":"62","author":"G Maria","year":"2003","unstructured":"Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003, 62 (2): 259-64. 10.1016\/S0090-4295(03)00477-1.","journal-title":"Urology"},{"key":"135_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8","volume":"37","author":"R Doggweiler","year":"1998","unstructured":"Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA: Botox-induced prostatic involution. Prostate. 1998, 37: 44-50. 10.1002\/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8.","journal-title":"Prostate"},{"issue":"4","key":"135_CR4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.urology.2004.10.077","volume":"65","author":"HC Kuo","year":"2005","unstructured":"Kuo HC: Prostate botulinum A toxin injection \u2013 an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005, 65 (4): 670-4. 10.1016\/j.urology.2004.10.077.","journal-title":"Urology"},{"issue":"3","key":"135_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/00365590902811537","volume":"43","author":"HC Kuo","year":"2009","unstructured":"Kuo HC, Liu HT: Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol. 2009, 43 (3): 206-11. 10.1080\/00365590902811537.","journal-title":"Scand J Urol Nephrol"},{"issue":"suppl","key":"135_CR6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-5347(18)35521-6","volume":"173","author":"F Guercini","year":"2005","unstructured":"Guercini F, Giannantoni A, Bard RL, Brisinda G, Cadeddu F, Maria G, Rossi P, Pajoncini C, Porena M: Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: a multicenter feasibility study. J Urol. 2005, 173 (suppl): 376-7.","journal-title":"J Urol"},{"key":"135_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.urology.2008.08.475","volume":"73","author":"G Brisinda","year":"2009","unstructured":"Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G: Relief by Botulinum Toxin of Lower Urinary Tract Symptoms Owing to Benign Prostatic Hyperplasia: Early and Long-Term Results. Urology. 2009, 73: 90-4. 10.1016\/j.urology.2008.08.475.","journal-title":"Urology"},{"key":"135_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.urology.2005.04.029","volume":"66","author":"YC Chuang","year":"2005","unstructured":"Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor B: Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostate. Urology. 2005, 66: 775-9. 10.1016\/j.urology.2005.04.029.","journal-title":"Urology"},{"key":"135_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/j.1464-410X.2006.06479.x","volume":"98","author":"YC Chuang","year":"2006","unstructured":"Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB: Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int. 2006, 98: 1033-7. 10.1111\/j.1464-410X.2006.06479.x.","journal-title":"BJU Int"},{"key":"135_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3349\/ymj.2006.47.5.706","volume":"47","author":"DS Park","year":"2006","unstructured":"Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK: Evaluation of short-term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yons Med J. 2006, 47: 706-14. 10.3349\/ymj.2006.47.5.706.","journal-title":"Yons Med J"},{"key":"135_CR11","volume-title":"Toxicon","author":"MF Brin","year":"2009","unstructured":"Brin MF: Development of future indications for BOTOX\u00ae. Toxicon. 2009,"},{"issue":"1","key":"135_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eururo.2007.08.050","volume":"53","author":"J Silva","year":"2008","unstructured":"Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P, Cruz F: Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol. 2008, 53 (1): 153-9. 10.1016\/j.eururo.2007.08.050.","journal-title":"Eur Urol"},{"key":"135_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.eururo.2008.06.016","volume":"54","author":"A Oeconomou","year":"2008","unstructured":"Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P: Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature. Eur Urol. 2008, 54: 765-777. 10.1016\/j.eururo.2008.06.016.","journal-title":"Eur Urol"},{"key":"135_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2490-6-12","volume":"6","author":"YC Chuang","year":"2006","unstructured":"Chuang YC, Tu CH, Huang CC, Lin HJ, Chiang PH, Yoshimura N, Chancellor MB: Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urology. 2006, 6: 12-10.1186\/1471-2490-6-12.","journal-title":"BMC Urology"},{"key":"135_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.eururo.2008.07.003","volume":"56","author":"J Silva","year":"2009","unstructured":"Silva J, Pinto R, Carvallho T, Coelho A, Avelino A, Dinis P, Cruz F: Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. Eur Urol. 2009, 56: 134-141. 10.1016\/j.eururo.2008.07.003.","journal-title":"Eur Urol"},{"key":"135_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.eururo.2007.12.007","volume":"54","author":"LP Witte","year":"2008","unstructured":"Witte LP, Chapple CR, de la Rosette JJ, Michel MC: Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol. 2008, 54: 326-34. 10.1016\/j.eururo.2007.12.007.","journal-title":"Eur Urol"},{"issue":"4","key":"135_CR17","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.juro.2008.06.033","volume":"180","author":"S Loeb","year":"2008","unstructured":"Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC: Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol. 2008, 180 (4): 1314-7. 10.1016\/j.juro.2008.06.033.","journal-title":"J Urol"},{"issue":"6 Sup 1","key":"135_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0090-4295(01)01347-4","volume":"58","author":"SA Kaplan","year":"2001","unstructured":"Kaplan SA: 5\u03b1-reductase inhibitors: What role should they play?. Urology. 2001, 58 (6 Sup 1): 65-70. 10.1016\/S0090-4295(01)01347-4.","journal-title":"Urology"},{"key":"135_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2007.03.002","volume":"52","author":"ATL Lin","year":"2007","unstructured":"Lin ATL, Yang AH, Chen K-K: Effects of botulinum toxin A on the contractile function of dog prostate. Eur Urol. 2007, 52: 582-9. 10.1016\/j.eururo.2007.03.002.","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"135_CR20","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1038\/sj.bjp.0706619","volume":"147","author":"MC Michel","year":"2006","unstructured":"Michel MC, Vrydag W: Alpha1-, alpha2- and beta-adrenoceptores in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006, 147 (Suppl 2): S88-119. 10.1038\/sj.bjp.0706619.","journal-title":"Br J Pharmacol"},{"issue":"6 Sup 1","key":"135_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0090-4295(01)01300-0","volume":"58","author":"MJ Barry","year":"2001","unstructured":"Barry MJ: Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology. 2001, 58 (6 Sup 1): 25-32. 10.1016\/S0090-4295(01)01300-0.","journal-title":"Urology"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-9-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2490-9-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-9-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2490-9-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:31:59Z","timestamp":1630445519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/1471-2490-9-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,15]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["135"],"URL":"https:\/\/doi.org\/10.1186\/1471-2490-9-9","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,15]]},"assertion":[{"value":"30 April 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"9"}}